A mechanism-based cancer risk assessment for 1,4-dichlorobenzene

Regulatory Toxicology and Pharmacology

Volumn 49, Issue 2, 2007, Pages 138-148

  Butterworth, Byron E ^a   Aylward, Lesa L ^b   Hays, Sean M ^b  

^a Butterworth Consulting   (United States)

^b LLP   (United States)

Author keywords

1,4 Dichlorobenzene; Cancer risk assessment; Nongenotoxic mitogenic carcinogens

Indexed keywords

1,4 DICHLOROBENZENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER MODEL; CANCER RISK; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENOTOXICITY; LIVER CANCER; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; BENCHMARKING; CARCINOGENS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHALATION EXPOSURE; INSECTICIDES; LIVER NEOPLASMS; MALE; MICE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RISK ASSESSMENT; TOXICOLOGY;

MUS;

EID: 35548943113     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2007.06.004     Document Type: Article

References (39)

1. Aiso S., Takeuchi T., Arito H., Nagano K., Yamamoto S., and Matsushima T. Carcinogenicity and chronic toxicity in mice and rats exposed by inhalation to para-dichlorobenzene for two years. J. Vet. Met. Sci. 67 (2005) 1019-1029
2. Ashby J., and Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257 (1991) 229-306
3. Beraterkreis Toxikologie, 2003. Position paper of the Beraterkreis Toxikologie of the AGS on the classification of 1,4-dichlorobenzene (p-DCB; CAS-No. 106-46-7) regarding mutagenicity and carcinogenicity. ECBI/78/02.
4. Bomhard E., Luckhaus G., Voigt W., and Loser E. Induction of light hydrocarbon nephorpathy by p-dichlorobenzene. Arch. Toxicol. 61 (1988) 433-439
5. Borghoff S.J., Short B.G., and Swenberg J.A. Biochemical mechanisms and pathobiology of alpha-2u-globulin nepropathy. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 349-367
6. Butterworth B.E. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens. Regul. Toxicol. Pharmacol. 45 (2006) 9-23
7. Butterworth B.E., Conolly R.B., and Morgan K.T. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments. Cancer Lett. 93 (1995) 129-146
8. Butterworth B.E., and Bogdanffy M.S. A comprehensive approach for integration of toxicity and cancer risk assessments. Regul. Toxicol. Pharmacol. 29 (1999) 23-36
9. Cattley R.C., Marsman D.M., and Popp J.A. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator Wy-14,643 in rat liver. Carcinogenesis 12 (1991) 469-473
10. Charbonneau M., Strasser J., Lock E.A., Turner M.J., and Swenberg J.A. Involvement of reversible binding to alpha-2u-globulin in 1,4-dichlorobenzene-induced nephortoxicity. Toxicol. App. Pharmacol. 99 (1989) 122-132
11. Commonwealth of Australia, 2000. National Industrial Chemical Notification and Assessment Scheme (NICNAS), December 2000, Commonwealth of Australia, 134 pp.
12. Dearfield K.L., Auletta A.E., Mimino M.C., et al. Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat. Res. 258 (1991) 259-283
13. Drinkwater N.R. Genetic control of hepatocarcinogenesis in C3H mice. Drug Metabol. Rev. 26 (1994) 201-208
14. Elcombe C.R., Odum J., Foster J.R., Stone S., Hasmall S., Soames A.R., Kimber I., and Ashby J. Prediction of rodent nongenotoxic carcinogeneis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Exp. Health Perspect. 110 (2002) 363-375
15. Eldridge S.R., Goldsworthy T.L., Popp J.A., and Butterworth B.E. Mitogenic stimulation of hepatocellular proliferation in rodents following 1,4-dichlorobenzene administration. Carcinogenesis 13 (1992) 409-415
16. European Union Risk Assessment Report: 1,4-dichlorobenzene, 2004. Vol. 48, European Commission Joint Research Centre, European Chemicals Bureau, 158 pp.
17. Gustafson D.L., Coulson A.L., Feng L., et al. Use of medium-term liver focus bioassay to assess the hepatocarcinogenicity of 1,2,4,5-tetrachlorobenzene and 1,4-dichlorobenzene. Cancer Lett. 129 (1998) 39-44
18. Holsapple M.P., Pitot H.C., Cohen S.M., Boobis A.R., Klaunig J.E., Pastoor T., Dellarco V.L., and Dragan Y.P. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 89 (2006) 51-56
19. International Programme on Chemical Safety (IPCS), 1999. IPCS workshop on developing a conceptual framework for cancer risk assessment. February 16-18, 1999, Lyon, France. IPCS/99.6 World Health Organizations Geneva, Switzerland
20. 1 mice (two-year inhalation studies). Japan Industrial Safety and Health Association. Unpublished summary.
21. Kirkland D., Aardema M., Henderson L., and Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584 (2005) 1-256
22. Lake B.G., Cunningham M.E., and Price R.J. Comparison of the hepatic and renal effects of 1,4-dichlorobenzene in the rat and mouse. Fundam. Appl. Toxicol. 39 (1997) 67-75
23. 1 mice. Comparison of administration by gavage in corn oil vs. ad libitum in drinking water. Fundam. Appl. Toxicol. 22 (1994) 90-102
24. Marsman D.S., and Popp J.A. Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, Wy-14,643. Carcinogenesis 15 (1994) 111-117
25. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., and Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 33 (2003) 591-653
26. Monsanto Company, 1996. One year study of p-dichlorobenzene administered orally via capsule to beagle dogs. Naylor, M.W., Stout, L.D., (Eds.), Monsanto Company, Experimental Health Laboratory, St. Louis, MO, Study No. ML-94-210, MRID No. 439888-02.
27. National Cancer Institute (NCI) SEER Program, 2007. http://seer.cancer.gov/publications/ethnicity/liver.pdf.
28. 1 mice. NTP TR 319, NIH Publication No. 87-2575.
29. Schulte-Hermann R., and Parzefall W. Failure to discriminate initiation from promotion of liver tumors in a long term study with the phenobarbital-type-inducer alpha-hexachlorocyclohexane and the role of sustained stimulation of hepatic growth an monoxygenases. Cancer Res. 41 (1981) 4140-4146
30. Schulte-Hermann R., Ohde G., Schuppler J., and Timmerman-Trosiener I. Enhanced proliferation of putative preneoplastic cells in rat liver following treatment with the tumor promoters phenobarbital, hexachlorocyclohexane, steroid compounds, and nafenopin. Cancer Res. 41 (1981) 2556-2562
31. Schulte-Hermann R., Schuppler J., Ohde G., Bursch W., and Timmermann-Trosiener I. Phenobarbital and other liver tumor promoters. In: Nicolini C. (Ed). Chemical Carcinogenesis (1982), Plenum Press, New York 231-260
32. Schulte-Hermann R., Schuppler J., Timmermann-Trosiener I., Ohde G., Bursch W., and Berger H. The role of growth of normal and preneoplastic cell populations for tumor promotion in rat liver. Environ. Health Perspect. 50 (1983) 185-194
33. Tennant R.W. Stratification of rodent carcinogenicity bioassay results to reflect relative human hazard. Mutat. Res. 286 (1993) 111-118
34. U.S. Environmental Protection Agency (U.S. EPA), 2005. Guidelines for Carcinogen Risk Assessment, EPA/630/P-03/00F, March 2005, U.S. Environmental Protection Agency, Washington, DC.
35. U.S. Environmental Protection Agency (U.S. EPA), 2006a. Draft Summary IRIS Document on 1,4-Dichlorobenzene, April 2006.
36. U.S. Environmental Protection Agency (U.S. EPA), 2006b. Toxicological Review of Dichlorobenzenes. In support of summary information of the Integrated Risk Information System (IRIS), Revised Final Draft, May 2006. EPA/635/R-03/015.
37. U.S. Environmental Protection Agency (U.S. EPA), 2006c. External Peer Review, Toxicological Review and IRIS Summary for 1,4-Dichlorobenzene (Inhalation Cancer Assessment and RfC), Final Report, Prepared by ORISE IRIS Technical Assistance Team, Oak Ridge Institute for Science and Education, Oak ridge Associated Universities, November 2006, 14 pp.
38. Watanabe K., and Williams G.M. Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital. Evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. J. Natl. Cancer Inst. 61 (1978) 1311-1314
39. Waters M.D., Stack H.F., Garrett N.E., and Jackson M.A. The genetic activity profile database. Environ. Health Perspect. 96 (1991) 41-45